Drostanolone breast cancer

Within bodybuilding, weight lifting and other sports communities, the use of Drostanolone propionate is valued for its assistance in building harder muscle mass and increasing overall muscle density. As a result, the androgenic steroid is particularly desirable among individuals looking to improve their overall muscular strength without “bulking up” excessively or increasing muscle mass. In addition, the use of Drostanolone propionate is popular among bodybuilding enthusiasts, as regular use of the steroid can create a more chiseled physique by helping to build denser musculature.

Like other AAS, drostanolone is an agonist of the androgen receptor (AR). [3] It is not a substrate for 5α-reductase and is a poor substrate for 3α-hydroxysteroid dehydrogenase (3α-HSD), and therefore shows a high ratio of anabolic to androgenic activity. [3] As a DHT derivative, drostanolone is not a substrate for aromatase and hence cannot be aromatized into estrogenic metabolites . [3] While no data are available on the progestogenic activity of drostanolone, it is thought to have low or no such activity similarly to other DHT derivatives. [3] Since the drug is not 17α-alkylated , it is not known to cause hepatotoxicity . [3]

Dromostanolone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, dromostanolone binds to the androgen receptor. This causes downstream genetic transcriptional changes. This ultimately causes retention of nitrogen, potassium, and phosphorus; increases protein anabolism; and decreases amino acid catabolism. The antitumour activity of dromostanolone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.

Drostanolone breast cancer

drostanolone breast cancer


drostanolone breast cancerdrostanolone breast cancerdrostanolone breast cancerdrostanolone breast cancerdrostanolone breast cancer